C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection

C5a 激活的吞噬细胞在全身性真菌感染期间驱动清除性免疫。

阅读:3
作者:Jigar V Desai,Dhaneshwar Kumar,Tilo Freiwald,Daniel Chauss,Melissa D Johnson,Michael S Abers,Julie M Steinbrink,John R Perfect,Barbara Alexander,Vasiliki Matzaraki,Brendan D Snarr,Marissa A Zarakas,Vasileios Oikonomou,Lakmali M Silva,Raju Shivarathri,Emily Beltran,Luciana Negro Demontel,Luopin Wang,Jean K Lim,Dylan Launder,Heather R Conti,Muthulekha Swamydas,Micah T McClain,Niki M Moutsopoulos,Majid Kazemian,Mihai G Netea,Vinod Kumar,Jörg Köhl,Claudia Kemper,Behdad Afzali,Michail S Lionakis

Abstract

Systemic candidiasis is a common, high-mortality, nosocomial fungal infection. Unexpectedly, it has emerged as a complication of anti-complement C5-targeted monoclonal antibody treatment, indicating a critical niche for C5 in antifungal immunity. We identified transcription of complement system genes as the top biological pathway induced in candidemic patients and as predictive of candidemia. Mechanistically, C5a-C5aR1 promoted fungal clearance and host survival in a mouse model of systemic candidiasis by stimulating phagocyte effector function and ERK- and AKT-dependent survival in infected tissues. C5ar1 ablation rewired macrophage metabolism downstream of mTOR, promoting their apoptosis and enhancing mortality through kidney injury. Besides hepatocyte-derived C5, local C5 produced intrinsically by phagocytes provided a key substrate for antifungal protection. Lower serum C5a concentrations or a C5 polymorphism that decreases leukocyte C5 expression correlated independently with poor patient outcomes. Thus, local, phagocyte-derived C5 production licenses phagocyte antimicrobial function and confers innate protection during systemic fungal infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。